Summary of Study ST000898
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000624. The data can be accessed directly via it's Project DOI: 10.21228/M8109M This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST000898 |
| Study Title | TAp73 is a marker of glutamine addiction in medulloblastoma |
| Study Type | siRNA constructs targeting p73 (ID: 2671-AMBION) and a non-targeting control siRNA (scramble) were transfected with 10 pM siRNA with lipofectamine 3000 according to the supplier’s protocol for 48 hours |
| Study Summary | Metabolically-targeted therapies hold the promise of offering an effective and less toxic treatment for tumours including medulloblastoma, the most common malignant brain tumour of childhood. Current treatment relies on the sensitivity of these tumours to DNA damage that was discovered more than 50 years ago. Finding new tumour-specific susceptibilities to complement sensitivity to DNA damage is key to developing new more effective adjuvant therapies. The specific metabolic program of tumours is an attractive vulnerability, as restriction diet are low cost and easy to implement. Here, we present compelling pre-clinical evidence that glutamine restriction diet can be used as an adjuvant treatment for p73-expressing medulloblastoma. |
| Institute | Queen Mary University of London |
| Department | Blizard Institute |
| Laboratory | Centre for Genomics and Child Health |
| Last Name | Marino |
| First Name | Silvia |
| Address | 4 Newark Street, E1 2AT, London |
| s.marino@qmul.ac.uk | |
| Phone | +44 20 7882 2360 |
| Submit Date | 2017-08-24 |
| Num Groups | 2 |
| Total Subjects | 18 |
| Study Comments | We include 3 biological replicate with 3 technical replicates for each condition. |
| Raw Data Available | Yes |
| Analysis Type Detail | LC-MS |
| Release Date | 2017-11-20 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000949 |
| Treatment Summary: | siRNA constructs targeting p73 (ID: 2671-AMBION) and a non-targeting control siRNA (scramble) were transfected with 10 pM siRNA with lipofectamine 3000 according to the supplier’s protocol for 48 hours |
| Cell Growth Container: | plate |
| Cell Growth Config: | attached |
| Cell Growth Rate: | 36 hours |
| Cell Inoc Proc: | lipofectamine 3000 |
| Cell Media: | DMEM + GlutaMAX medium (Gibco), supplemented with 10% v/v foetal bovine serum (FBS, Gibco) and penicillin/streptomycin (1 U/ml, Gibco), |
| Cell Envir Cond: | 37°C in humidified 5% CO2 |
| Cell Harvesting: | After 48 h of transfection the cells were washed three times with ice-cold PBS (3x5 mL) and the celles were collected using a cell scraper. Ice-cold water (3 mL,sterile, MilliQ) was added to the samples. The suspension was transferred to a 15 mL polypropylene tube and then snap-frozen in liquid N2 and stored on ice for 5 min. The cells were lysed by two freeze-thaw cycles where the cells were thawed at 37°C in a water bath and frozen using liquid N2. Subsequently, the cells were sonicated in a |
| Cell Pct Confluence: | 80-90% |
| Cell Media Lastchanged: | 48 hours |
